$MRNA
Moderna, Inc. Stock $mrna

$mrna Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000168285219000009 Filed on March 13, 2019

Income Statement

Concept	2019 Q1	2017 Q4	2017 Q3
Revenue	$16.03M	$91.90M	$42.47M
YoY Change	-44.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$27.30M	$15.90M	$16.70M
YoY Change	67.48%
% of Gross Profit
Research & Development	$130.4M	$117.8M	$93.60M
YoY Change	44.7%
% of Gross Profit
Depreciation & Amortization	$7.300M	$5.900M	$5.100M
YoY Change	40.38%
% of Gross Profit
Operating Expenses	$157.7M	$133.7M	$110.3M
YoY Change	48.13%
Operating Profit	-$141.6M	-$41.83M	-$67.87M
YoY Change	82.99%
Interest Expense	$9.400M	$3.200M	$3.400M
YoY Change	80.77%
% of Operating Profit
Other Income/Expense, Net	-$1.931M	$500.0K	-$300.0K
YoY Change	955.19%
Pretax Income	-$132.6M	-$38.10M	-$64.80M
YoY Change	83.21%
Income Tax	-$24.00K	-$200.0K	$0.00
% Of Pretax Income
Net Earnings	-$132.6M	-$37.90M	-$64.80M
YoY Change	83.18%
Net Earnings / Revenue	-827.31%	-41.24%	-152.57%
Basic Earnings Per Share
Diluted Earnings Per Share	-$403.3K	-$116.8K	-$199.8K
COMMON SHARES
Basic Shares Outstanding	329.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.109B	$756.0M
YoY Change
Cash & Equivalents	$502.9M	$134.9M
Short-Term Investments	$606.0M	$621.2M
Other Short-Term Assets	$8.000M
YoY Change
Inventory
Prepaid Expenses	$7.895M	$7.839M
Receivables	$8.948M	$11.88M
Other Receivables	$17.00M
Total Short-Term Assets	$1.141B	$783.2M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$209.5M	$139.0M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$438.0M
YoY Change
Other Assets	$2.438M	$4.586M
YoY Change
Total Long-Term Assets	$879.1M	$301.3M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.141B	$783.2M
Total Long-Term Assets	$879.1M	$301.3M
Total Assets	$2.020B	$1.084B
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$38.51M	$20.73M
YoY Change
Accrued Expenses	$42.18M	$72.72M
YoY Change
Deferred Revenue	$81.78M
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$159.2M	$191.5M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$33.00M
YoY Change
Other Long-Term Liabilities	$213.0K	$1.530M
YoY Change
Total Long-Term Liabilities	$213.0K	$1.530M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$159.2M	$191.5M
Total Long-Term Liabilities	$213.0K	$1.530M
Total Liabilities	$360.2M	$459.2M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$982.4M	-$621.9M
YoY Change
Common Stock	$33.00K	$6.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.442B	-$551.4M
YoY Change
Total Liabilities & Shareholders Equity	$2.020B	$1.084B
YoY Change

Cashflow Statement

Concept	2019 Q1	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$132.6M	-$37.90M	-$64.80M
YoY Change	83.18%
Depreciation, Depletion And Amortization	$7.300M	$5.900M	$5.100M
YoY Change	40.38%
Cash From Operating Activities	-$144.3M	-$102.9M	-$42.70M
YoY Change	29.52%
INVESTING ACTIVITIES
Capital Expenditures	$7.595M	-$12.00M	-$29.10M
YoY Change	-76.2%
Acquisitions
YoY Change
Other Investing Activities	-$4.200M	$126.1M	$43.80M
YoY Change	-99.07%
Cash From Investing Activities	-$11.76M	$114.1M	$14.80M
YoY Change	-97.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$293.0K	1.600M	0.000
YoY Change	-99.95%
NET CHANGE
Cash From Operating Activities	-$144.3M	-102.9M	-42.70M
Cash From Investing Activities	-$11.76M	114.1M	14.80M
Cash From Financing Activities	$293.0K	1.600M	0.000
Net Change In Cash	-$155.7M	12.80M	-27.90M
YoY Change	245.35%
FREE CASH FLOW
Cash From Operating Activities	-$144.3M	-$102.9M	-$42.70M
Capital Expenditures	$7.595M	-$12.00M	-$29.10M
Free Cash Flow	-$151.9M	-$90.90M	-$13.60M
YoY Change	5.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001682852
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	329000469	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q4	dei	Entity Public Float EntityPublicFloat	4300000000	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	Moderna, Inc.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	14870000	USD
CY2018Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	21578000	USD
CY2017Q4	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	25000000	USD
CY2018Q4	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	22000000	USD
CY2017Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	14624000	USD
CY2018Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	12089000	USD
CY2017Q4	mrna	Deferred Tax Assets Capitalized Licenses Research And Development And Start Up Costs DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts	18732000	USD
CY2018Q4	mrna	Deferred Tax Assets Capitalized Licenses Research And Development And Start Up Costs DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts	22143000	USD
CY2017Q4	mrna	Deferred Tax Assets Lease Financing Obligation DeferredTaxAssetsLeaseFinancingObligation	0	USD
CY2018Q4	mrna	Deferred Tax Assets Lease Financing Obligation DeferredTaxAssetsLeaseFinancingObligation	9149000	USD
CY2016	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	3828000	USD
CY2017	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	2932000	USD
CY2018	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	2420000	USD
CY2017Q4	mrna	Lease Financing Obligation LeaseFinancingObligation	15687000	USD
CY2018Q4	mrna	Lease Financing Obligation LeaseFinancingObligation	33489000	USD
CY2016	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	12500000	USD
CY2017	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	1748000	USD
CY2018	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	10089000	USD
CY2016	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	0	USD
CY2017	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	1748000	USD
CY2018	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	10089000	USD
CY2016	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	0	USD
CY2017	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	1285000	USD
CY2018	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	2175000	USD
CY2016	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	0	USD
CY2017	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	2724000	USD
CY2018	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	11635000	USD
CY2015	mrna	Research And Development Arrangement Contract To Perform For Others Number Of Milestones Achieved ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestonesAchieved	2	milestone
CY2018Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	3.53
CY2018	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	2.36
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1157000	USD
CY2018	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue	7.58
CY2017Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	4.91
CY2018Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	6.59
CY2018Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	8.95
CY2016	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	89000	USD
CY2017	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	152000	USD
CY2018	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	2638000	USD
CY2017	mrna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	64100000	USD
CY2016	mrna	Tax Distributions Incurred But Notyet Paid TaxDistributionsIncurredButNotyetPaid	1464000	USD
CY2017	mrna	Tax Distributions Incurred But Notyet Paid TaxDistributionsIncurredButNotyetPaid	0	USD
CY2018	mrna	Tax Distributions Incurred But Notyet Paid TaxDistributionsIncurredButNotyetPaid	0	USD
CY2016	mrna	Temporary Equity Dividends And Accretion To Redemption Value TemporaryEquityDividendsAndAccretionToRedemptionValue	8663000	USD
CY2017	mrna	Temporary Equity Dividends And Accretion To Redemption Value TemporaryEquityDividendsAndAccretionToRedemptionValue	0	USD
CY2018	mrna	Temporary Equity Dividends And Accretion To Redemption Value TemporaryEquityDividendsAndAccretionToRedemptionValue	0	USD
CY2017Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	1748000	USD
CY2018Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	10089000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	20725000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31210000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11881000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11686000	USD
CY2017Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1536000	USD
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	899000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	72715000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	79073000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	48031000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	64456000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1320000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	71679000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2538155000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40013000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40055000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72565000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	152000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39360000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40055000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72565000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	233841103	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	240375353	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51478444	shares
CY2017Q4	us-gaap	Assets Assets	1084489000	USD
CY2018Q4	us-gaap	Assets Assets	1962149000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	863063000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	145851000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	172990000	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10014000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	863063000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	621170000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	783223000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1563006000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	768178000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1037372000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	146158000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	173369000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	145851000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	172990000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	767021000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	1036053000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	622020000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	864003000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	621170000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	19959000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12892000	USD
CY2016Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	0	USD
CY2017Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	0	USD
CY2018Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159043000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50080000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134859000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	658364000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-108963000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	84779000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	523505000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	696581112	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65206999	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	328798904	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65206999	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	328798904	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-216048000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-256670000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-384897000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	704000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-252000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-26000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	755000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-80000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	326000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	51000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	172000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	352000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	602000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	82800000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	300000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	400000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	173	security
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	25	security
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	288000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	288000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9485000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15228000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7586000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10006000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	96739000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	109056000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	242929000	USD
CY2018Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	165352000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7103000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	71209000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	208135000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	323501000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9485000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15228000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	100372000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	114932000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1997000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2870000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	47804000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	53617000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15637000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	33138000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	16490000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	16443000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	198650000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	308273000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9485000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	15228000	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.5
CY2018	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.06
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15100000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15114000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20537000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20500000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24900000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24862000	USD
CY2017	us-gaap	Distribution Made To Limited Liability Company Llc Member Cash Distributions Paid DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid	1500000	USD
CY2016	us-gaap	Dividends Dividends	363000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.79
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.18
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.16
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.14
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.95
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.402
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.204
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.285
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.250
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.005
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.030
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.013
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.005
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.085
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.043
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.048
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.015
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18221000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23406000	USD
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	217600000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y8M
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-891000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57450000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	64722000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	94252000	USD
CY2016	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-211786000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-247784000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-380473000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3382000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8212000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3935000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-215168000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-255996000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-384408000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1043000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-80000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	326000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	905000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	398000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	294000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5993000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12766000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15017000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8642000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1476000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-195000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-60979000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	1370000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-637000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5328000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	34369000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8787000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	164129000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-162321000	USD
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-65260000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1977000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-145000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	910000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7887000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-579000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5289000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	8902000	USD
CY2017	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1269000	USD
CY2018	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-622000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2998000	USD
CY2017Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	3239000	USD
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	7909000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	11312000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	15235000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	27023000	USD
CY2016	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2478000	USD
CY2017	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1086000	USD
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1866000	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2400000	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1000000	USD
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	700000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	459193000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	431908000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1084489000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1962149000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	191461000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	222803000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	472910000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	168000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1226842000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-648607000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	416095000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-372472000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	66734000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-331484000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-330865000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-216200000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-216211000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-255916000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-255900000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384734000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384700000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-230314000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-269841000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-401857000	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016	us-gaap	Operating Expenses OperatingExpenses	332167000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	95791000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	135315000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	110343000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	133732000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	475181000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	106441000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	125866000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	127575000	USD
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	188452000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	548334000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-223771000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-65463000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-94194000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-67871000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-41828000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-269356000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-77402000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-97015000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-85818000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-153031000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-413266000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	211769000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	20027000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	17235000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1530000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	20208000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	20937000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	20404000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	112958000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	13700000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	18600000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	19100000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4586000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2644000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	163000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-754000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-163000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	60000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	412000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	31000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	223000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-342000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-132000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1282000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3464000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	41322000	USD
CY2016	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1415461000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	727203000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1227709000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2709000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1875000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1835000	USD
CY2016	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2017	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2016	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	0	USD
CY2017	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	8182000	USD
CY2016	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	633000	USD
CY2017	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	1483000	USD
CY2018	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	0	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33144000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58401000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105766000	USD
CY2016	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	8663000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2017	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2018	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	4127000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12826000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28399000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7839000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10401000	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	563026000	USD
CY2016	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	473532000	USD
CY2017	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	661111000	USD
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	675200000	USD
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	800438000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	783373000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	133700000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	402530000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	177008000	USD
CY2016	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	11000	USD
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	212000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1427000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	187062000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	276433000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	139031000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	211977000	USD
CY2018Q4	us-gaap	Property Subject To Or Available For Operating Lease Number Of Units PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits	2	campus
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2018	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	1833561000	USD
CY2016	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	5440000	USD
CY2017	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	13925000	USD
CY2018	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	12996000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	274717000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	410459000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	454082000	USD
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	951000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	595000	USD
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11798000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11532000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-621893000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1006627000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1000000000	USD
CY2016	us-gaap	Revenues Revenues	108396000	USD
CY2017Q1	us-gaap	Revenues Revenues	30328000	USD
CY2017Q2	us-gaap	Revenues Revenues	41121000	USD
CY2017Q3	us-gaap	Revenues Revenues	42472000	USD
CY2017Q4	us-gaap	Revenues Revenues	91904000	USD
CY2017	us-gaap	Revenues Revenues	205825000	USD
CY2018Q1	us-gaap	Revenues Revenues	29039000	USD
CY2018Q2	us-gaap	Revenues Revenues	28851000	USD
CY2018Q3	us-gaap	Revenues Revenues	41757000	USD
CY2018Q4	us-gaap	Revenues Revenues	35421000	USD
CY2018	us-gaap	Revenues Revenues	135068000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	39360000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	40055000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	72565000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	58600000.0	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	22118203	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.86
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5300000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1639261	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	19223123	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.33
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	130587000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	220434000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33684134	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	50821132	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.31
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.16
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	40983000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	28705512	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.48
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.05
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	12.70
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.01
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	179459000	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	446864	shares
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	563026000	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	212000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1427000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-149760000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-334810000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-551365000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1530241000	USD
CY2016Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	10
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.4587
CY2017	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2016	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	8663000	USD
CY2017	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2018	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1176661000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1833561000	USD
CY2017Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	1209940000	USD
CY2018Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2018Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	1903887000	USD
CY2017Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	448686791	shares
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2018Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	509352795	shares
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	509352795	shares
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	448686791	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	508539515	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	448686791	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	508539515	shares
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	906000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	940000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	141000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	15000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	799000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	49000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	109600000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60747426	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64497544	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81114183	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio is comprised of money market funds, marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conformity with GAAP requires us to make estimates and judgments that affect the reported amounts and related disclosures in the consolidated financial statements and accompanying notes. We base our estimates and judgments on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that we believe to be reasonable under the circumstances. Our actual results could differ materially from estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value of financial instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.</font></div></div>

Files In Submission

Name	View Source	Status
0001682852-19-000009-index-headers.html	Edgar Link	pending
0001682852-19-000009-index.html	Edgar Link	pending
0001682852-19-000009.txt	Edgar Link	pending
0001682852-19-000009-xbrl.zip	Edgar Link	pending
a0001193125183449821_image43.jpg	Edgar Link	pending
a0001193125183449821_image44.jpg	Edgar Link	pending
a0001193125183449821_image45.jpg	Edgar Link	pending
a0001193125183449821_image46.jpg	Edgar Link	pending
a0001193125183449821_image49.jpg	Edgar Link	pending
a0001193125183449821_image50.jpg	Edgar Link	pending
a0001193125183449821_image51.jpg	Edgar Link	pending
a0001193125183449821_image53.jpg	Edgar Link	pending
a0001193125183449821_image54.jpg	Edgar Link	pending
a0001193125183449821_image55.jpg	Edgar Link	pending
a0001193125183449821_image56.jpg	Edgar Link	pending
a0001193125183449821_image57.jpg	Edgar Link	pending
a0001193125183449821_image58.jpg	Edgar Link	pending
a0001193125183449821_image60.jpg	Edgar Link	pending
a0001193125183449821_image61.jpg	Edgar Link	pending
a0001193125183449821_image63.jpg	Edgar Link	pending
a0001193125183449821_image64.jpg	Edgar Link	pending
a0001193125183449821_image65.jpg	Edgar Link	pending
a0001193125183449821_image66.jpg	Edgar Link	pending
a0001193125183449821_image67.jpg	Edgar Link	pending
a0001193125183449821_image68.jpg	Edgar Link	pending
a0001193125183449821_image69.jpg	Edgar Link	pending
a0001193125183449821_image73.jpg	Edgar Link	pending
a0001193125183449821_image74.jpg	Edgar Link	pending
a0001193125183449821_image75.jpg	Edgar Link	pending
a0001193125183449821_image76.jpg	Edgar Link	pending
a0001193125183449821_image78.jpg	Edgar Link	pending
a0001193125183449821_image79.jpg	Edgar Link	pending
a0001193125183449821_image81.jpg	Edgar Link	pending
a0001193125183449821_image82.jpg	Edgar Link	pending
a0001193125183449821_image83.jpg	Edgar Link	pending
a0001193125183449821_image85.jpg	Edgar Link	pending
a0001193125183449821_image86.jpg	Edgar Link	pending
a0001193125183449821_image87.jpg	Edgar Link	pending
a0001193125183449821_image88.jpg	Edgar Link	pending
a0001193125183449821_image89.jpg	Edgar Link	pending
a0001193125183449821_image90.jpg	Edgar Link	pending
a0001193125183449821_image92.jpg	Edgar Link	pending
a0001193125183449821_image93.jpg	Edgar Link	pending
a0001193125183449821_image95.jpg	Edgar Link	pending
a0001193125183449821_image96.jpg	Edgar Link	pending
a0001193125183449821_image97.jpg	Edgar Link	pending
a0001193125183449821_image98.jpg	Edgar Link	pending
a0001193125183449821_imagf01.jpg	Edgar Link	pending
a000119312518344982_001.jpg	Edgar Link	pending
a10kimage102a01.jpg	Edgar Link	pending
a10kimage103a01.jpg	Edgar Link	pending
a10kimage104a01.jpg	Edgar Link	pending
a10kimage105a01.jpg	Edgar Link	pending
a10kimage106a01.jpg	Edgar Link	pending
a10kimage107a01.jpg	Edgar Link	pending
a10kimage108a01.jpg	Edgar Link	pending
a10kimage109a01.jpg	Edgar Link	pending
a10kimage11.jpg	Edgar Link	pending
a10kimage110a01.jpg	Edgar Link	pending
a10kimage111a01.jpg	Edgar Link	pending
a10kimage12.jpg	Edgar Link	pending
a10kimage13.jpg	Edgar Link	pending
a10kimage14.jpg	Edgar Link	pending
a10kimage15.jpg	Edgar Link	pending
a10kimage16.jpg	Edgar Link	pending
a10kimage17.jpg	Edgar Link	pending
a10kimage18.jpg	Edgar Link	pending
a10kimage19.jpg	Edgar Link	pending
a10kimage20.jpg	Edgar Link	pending
a10kimage22.jpg	Edgar Link	pending
a10kimage23.jpg	Edgar Link	pending
a10kimage24.jpg	Edgar Link	pending
a10kimage25.jpg	Edgar Link	pending
a10kimage26.jpg	Edgar Link	pending
a10kimage27.jpg	Edgar Link	pending
a10kimage28.jpg	Edgar Link	pending
a10kimage99.jpg	Edgar Link	pending
a190203enginesimagea01.jpg	Edgar Link	pending
a190207pcv.jpg	Edgar Link	pending
a190207pcvii.jpg	Edgar Link	pending
a190215hmpvph1trialdesign.jpg	Edgar Link	pending
a190301pcv.jpg	Edgar Link	pending
a190303cmvph1.jpg	Edgar Link	pending
a190305cellmap.jpg	Edgar Link	pending
a190305pipeline.jpg	Edgar Link	pending
a190309chikv.jpg	Edgar Link	pending
a190309zikaourproductconcept.jpg	Edgar Link	pending
a190311krasvaccinefigure2019.jpg	Edgar Link	pending
a190312capture.jpg	Edgar Link	pending
a190312g67g21.jpg	Edgar Link	pending
a190312g67g212a01.jpg	Edgar Link	pending
apatentsissuedorallowea01.jpg	Edgar Link	pending
chart-286a257a262b864dc82.jpg	Edgar Link	pending
exhibit102312312018.htm	Edgar Link	pending
exhibit23112312018.htm	Edgar Link	pending
exhibit31112312018.htm	Edgar Link	pending
exhibit31212312018.htm	Edgar Link	pending
exhibit32112312018.htm	Edgar Link	pending
exhibit32212312018.htm	Edgar Link	pending
figuresforword20180731cmv.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image0001b.jpg	Edgar Link	pending
moderna10-k12312018.htm	Edgar Link	pending
modernalogo.jpg	Edgar Link	pending
modularsynthesisproteinprod2.jpg	Edgar Link	pending
mrna-20181231.xml	Edgar Link	completed
mrna-20181231.xsd	Edgar Link	pending
mrna-20181231_cal.xml	Edgar Link	unprocessable
mrna-20181231_def.xml	Edgar Link	unprocessable
mrna-20181231_lab.xml	Edgar Link	unprocessable
mrna-20181231_pre.xml	Edgar Link	unprocessable
platformoverviewimage.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rsv.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
translationlangcompariso.jpg	Edgar Link	pending
translationlangcomparisoa01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNA
Moderna, Inc. Stock $mrna

2019 Q1 Form 10-K Financial Statement

#000168285219000009 Filed on March 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA Moderna, Inc. Stock $mrna

2019 Q1 Form 10-K Financial Statement

#000168285219000009 Filed on March 13, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA
Moderna, Inc. Stock $mrna